We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An Experimental Vaccine Expressing Wild-Type p53 Induces Protective Immunity against Glioblastoma Cells with High Levels of Endogenous p53.
- Authors
BLASZCZYK-THURIN, M; O, I; ERTL, H
- Abstract
Inoculation of mice with a recombinant vaccinia virus expressing the full-length mouse wild-type p53 protein (Vp53-wt) was shown to induce partial protection against peripheral challenge with a mouse glioblastoma cell line, termed GL261, expressing high levels of nuclear, endogenous wild-type p53. In vivo experiments with knockout (KO) mice and mice treated with depleting doses of antibodies specific to lymphocyte subsets revealed that vaccine efficacy depended on CD4 + and CD8 + T cells as well as on natural killer (NK) cells. Vp53-wt virus-vaccinated mice that failed to develop tumours upon challenge with a minimal tumourigenic dose of GL261 cells remained completely resistant to further challenge with increased doses of GL261 cells. The efficacy of the Vp53-wt vaccine was improved by adding recombinant mouse interleukin-12 (rIL-12) as an adjuvant at the time of tumour challenge. The induction of T cells to p53 in Vp53-wt virus-immune mice was also demonstrated at the tumour site by immunochemistry and was further confirmed by a delayed-type hypersensitivity response to the p53 protein, although in vitro experiments using splenocytes from vaccinated mice failed to demonstrate CD4 + or CD8 + T-cell activity to p53.
- Subjects
VIRAL vaccines; CELLULAR immunity
- Publication
Scandinavian Journal of Immunology, 2002, Vol 56, Issue 4, p361
- ISSN
0300-9475
- Publication type
Article
- DOI
10.1046/j.1365-3083.2002.01119.x